Ninlaro (ixazomib) — United Healthcare

Initial criteria

• Diagnosis of relapsed or refractory systemic light chain amyloidosis

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Ninlaro therapy

Approval duration

12 months